Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 5, 2005, Pages 872-878

  Edmiston Jr , Charles E ^a,b   Krepel, Candace J ^a   Kehl, Karen S ^a   Seabrook, Gary R ^a   Somberg, Lewis B ^a   Almassi, G Hossein ^a   Smith, Timothy L ^a   Loehrl, Todd A ^a   Brown, Kellie R ^a   Lewis, Brian D ^a   Towne, Jonathan B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Division of Vascular Surgery   (United States)

Author keywords

In vitro susceptibility; MICs; Surgical infections

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; GARENOXACIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LARYNGOPLASTY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; SURGICAL INFECTION; THORAX SURGERY; VASCULAR SURGERY;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; FLUOROQUINOLONES; HUMANS; IMIPENEM; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; QUINOLINES;

EID: 27744575539     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki348     Document Type: Article

References (22)

1. Condon RE. Microbiology in intraabdominal infections: What is the message for clinical studies? Infection 1999; 27: 63-6.
2. Edmiston CE, Krepel C, Seabrook GR et al. Anaerobic infections in the surgical patient: Microbial etiology and therapy. Clin Infect Dis 2002; 35: S1-S7.
3. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
4. DiPiro JT, Edmiston CE, Bohnen JMA. Pharmacodynamics of antimicrobial therapy in surgery. Am J Surg 1996; 171: 615-22.
5. Edmiston CE, Suarez EC, Walker AP et al. Penetration of fleroxacin and ciprofloxacin into biliary tract. Antimicrob Agents Chemother 1996; 40: 787-8.
6. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51: 1-11.
7. Nichols RL. The role of quinolones in abdominal surgery. Surg Infect 2000; 1: 65-72.
8. Wexler HME, Molitoris E, Molitoris D et al. In-vitro activity of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996; 40; 2232-5.
9. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.
10. Christiansen KJ, Bell JM, Turnidge JD et al. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob Agents Chemother 2004; 48: 2049-55.
11. Goldstein EJ, Citron DM, Merriam CV et al. In-vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob Agents Chemother 2002; 46: 866-70.
12. Hecht DW, Osmolski JR. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob Agents Chemother 2003; 47: 910-16.
13. Liebetrau A, Rodloff AC, Behra-Miellet J et al. In-vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother 2003; 47: 3667-71.
14. Weller TM, Andrews JM, Jevons G et al. The in-vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 2002; 49: 177-84.
15. Gajjar DA, Bello A, Ge Z et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003; 47: 2256-63.
16. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA, 2000.
17. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Fifth Edition: Approved Standard M11-A5. NCCLS, Wayne, PA, USA, 2001.
18. Edmiston CE, Seabrook GR, Hennen, C. The importance of β-lactamase resistance in surgical infections. Surg Infect 2001; 2: 1-10.
19. Snydman DR, Jacobus NV, McDermott LA et al. In-vitro activity of newer quinolones against Bacteroides group organism. Antimicrob Agents Chemother 2002; 46: 3276-9.
20. Golan Y, McDermott LA, Jocubus NV et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003; 52: 208-13.
21. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome development. Clin Infect Dis 2004; 39: 92-7.
22. Joukhadar CJ, Stass H, Muller-Zellenberg U et al. Penetration of moxifloxacin into healthy and inflammed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003; 47: 3099-3103.